Abstract: Classical ETV-resistance mutations rtT184/S202/M250substitution+rtM204V/I+-L180M (LAM-r), rtA186T, and rtI163V were detected in 1252 (5.69%), 14 (0.06%), and 230 (1.05%) of the 22,009 patients, respectively.
Abstract: Compared to wild-type strain, two patient-derived mutants' rtL180M+A186T+M204V and rtL180M+T184S+A186T+M204V had 86.7% and 89.2% decreased replication capacity, 210
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
Abstract: RESULTS: Five mutations (rtS106C [C], rtH126Y [Y], rtD134E [E], rtM204I/V, and rtL269I [I]) were commonly found in viral isolates from 2 patients.
CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
PMID: 30670420
2019
Antimicrobial agents and chemotherapy
Abstract: CMCdG also reduced the level of HBVETV-R L180M/S202G/M204V viremia by ~1 log in HBVETV-R L180M/S202G/M204V-infected human liver-chimeric mice, while ETV (1 mg/kg/day q.d.) completely failed to reduce the viremia.
Abstract: CMCdG potently inhibited HBV production in HepG2.2.15 cells (50% inhibitory concentration [IC50], ~30 nM) and HBVWT Ce plasmid-transfected Huh7 cells (IC50, 206 nM) and efficiently suppressed ETV-resistant HBVETV-R L180M/S202G/M204V (IC50, 2,657 nM), while it showed no or little cytotoxicity (50% cytotoxic concentration, >500 muM in most hepatocytic cells examined).
Abstract: CMCdG's in vitro activity was determined using quantitative PCR a
Synthesis of an Anti-hepatitis B Agent, 2'-Fluoro-6'-methylene-carbocyclic Adenosine (FMCA) and Its Phosphoramidate (FMCAP).
PMID: 30589264
2019
The Journal of organic chemistry
Abstract: 2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA, 12) and its phosphoramidate prodrug (FMCAP, 14) have been proven as a potential anti-HBV agent against both adefovir-resistant as well as lamivudine-resistant double (rtL180M/rtM204V) mutants.
Abstract: Furthermore, in vitro, these agents have demonstrated significant activity against lamivudine/entecavir triple mutants (L180M + S202G + M204V).
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Abstract: Eight mutations in RT (rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V, and rtM309K) are significantly associated with HCC progression.
Method: A systematic review by Zhang et al revealed that the global incidence of rtPolymerase with L180M/M204V Mutations.
Abstract: It is frequently found in combination with rtM204I/V substitution under NUC treatment.
Abstract: RESULTS: Among 261 NUC-treated CHB patients, we found a high detection rate of rtM204I/V substitution (30.7% [80/261]).
Abstract: We identified a new substitution of rtH55R, and its detection rate had a significantly increasing trend from 3.8% (9/240) in the untreated group to 7.2% (13/181) or 33.8% (27/80) in the treated group with rtM204 or with rtM204I/V substitutions (P<0.0001).
Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016).
Abstract: Among the primary NA-resistant mutations, rtM204I (13.44%, 545/4055) occurred more frequently, followed by rtM204V, rtN236T, rtA181T, and rtA181V.
Abstract: For single-base mutations, rtL180M and rtA181V increased gradually during the past seven years, while rtM204I/V and rtN236T decreased after 2015.
Abstract: Moreover, single-base mu
Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
Abstract: The percentage of resistance to Lamivudine was high (40%) and varied according to the M204V/I motif.
Introduction: A high rate (47.4%) of the mutation conferring resistance to Lam
Result: All patients with RAM M204V/I received 3TC-based therapy.
Result: The analysis of HBV strains for the S/Pol gene by the MRT online software showed that of the major RAMs, M204V/I was the most frequent (4/10, 40%), followed by its compensatory RAMs; L180M (3/10, 30%) and V173L (2/10, 20%).
Discussion: For 3 patients, mutations M204V and M180V were present, for 1 patient only the M204I mutation was detected.
2'-Fluoro-6'-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent, active against drug-resistant HBV mutants.
Result: Among 48 HIV co-infected subjects analyzed, 31.3% (15) of them developed 3TC/ETV resistance at YMDD RT motif due to rtM204V/I+rt
Table: M204V
Discussion: Moreover, with a proportional HBeAg positive and negative status, 29.3% of HIV co-infected patients included in the current study were reported to have 3TC/ETV resistance due to rtM204V/I+rtL180M+rtV173L mutant gene variants.
HBV mutation literature information.
PMID: 
2019
Antiviral research
Browser Board
Co-occurred Entities
Filtrator
ViMRT